Supravalvular Aortic Stenosis (SVAS) #3: Preop Assessment & Anesthesia Risk

SVAS is a fixed LV outflow obstruction above the aortic valve, classically at the sinotubular junction/proximal ascending aorta. In the Williams–Beuren spectrum, SVAS is frequently part of a diffuse elastin arteriopathy that can involve the coronary ostia/proximal coronaries and the branch pulmonary arteries, creating a narrow physiologic margin during sedation and induction [1]. The key mechanism of peri-induction collapse is myocardial oxygen supply–demand imbalance in a hypertrophied ventricle with precarious coronary perfusion—often worsened by concomitant coronary lesions and/or biventricular outflow obstruction [2–4].

1) Why Induction Is the “Cliff Edge” in SVAS

1.1 Demand side: oxygen requirement is intrinsically high

• Fixed afterload → the LV must generate markedly elevated systolic pressure to maintain forward flow.
• Chronic pressure load → concentric LV hypertrophy
• ↑ myocardial mass → ↑ basal oxygen consumption
• ↓ compliance → ↑ LVEDP → worsened subendocardial perfusion
• Common triggers that spike demand: tachycardia, agitation/pain, fever, anemia, hypovolemia [2–4].

1.2 Supply side: coronary perfusion is fragile

A practical hemodynamic anchor is:

• CPP ≈ Aortic diastolic pressure − LVEDP

In SVAS (especially with LVH):

• LVEDP is often elevated (diastolic dysfunction).
• Induction can reduce aortic diastolic pressure via vasodilation (↓SVR).
• Net effect: CPP drops abruptly, and ischemia may precede obvious global instability [2–4].

1.3 Induction concentrates multiple adverse transitions

Typical induction conditions can simultaneously produce:

• ↓SVR/↓diastolic pressure (vasodilation)
• ↓preload (fasting + vasodilation + positive-pressure ventilation)
• tachycardia (sympathetic surges from stimulation or inadequate depth)

This triad is exactly what a hypertrophied SVAS ventricle tolerates poorly [2–4].

2) “Doubly-Obstructed” Physiology: SVAS + Branch PA Stenosis

When branch PA stenosis coexists (common in Williams spectrum arteriopathy):

• RV afterload is fixed/elevated → limited RV reserve.
• Hypoxia/hypercarbia/acidosis can raise PVR further → RV stress escalates.
• RV output fall → LV preload falls, systemic output collapses.

Clinical implication: hemodynamic collapse may be rapid and can occur with limited early warning if diastolic pressure and coronary perfusion are not actively protected [2–5].

3) Preoperative Assessment: Define Anatomy, Define Coronary Risk, Define Induction Plan

A diagnosis of “SVAS on echo” is not sufficient. Pre-op evaluation should answer whether this is focal SVAS or diffuse arteriopathy with coronary vulnerability [1–4].

3.1 Lesion characterization (LVOT and great vessels)

• SVAS phenotype: discrete ring vs hourglass vs diffuse ascending narrowing
• Severity: gradients + caliber of ST junction/ascending aorta
• Associated disease: aortic valve pathology, arch disease, systemic arterial stenoses
• Branch PA stenosis: distribution, severity, RV impact [1,4].

3.2 Coronary risk stratification (the load-bearing step)

Coronary compromise in this population may be ostial and/or proximal and can be clinically silent until physiologic stress unmasks it [1–4]. Red flags that should escalate coronary evaluation and anesthetic precautions include:

• Severe SVAS with marked LVH/strain
• Symptoms (exertional intolerance, chest pain equivalents, syncope, irritability with feeds)
• ECG ischemic changes or ventricular dysfunction
• High-risk syndromic phenotype or prior adverse anesthetic events [2–4].

Practical standard: align the imaging pathway (echo review ± CT/cath per institutional algorithm) with anesthesia/cardiology/surgery before the patient arrives in the OR [3,4].

4) Anesthetic Objectives: A Strict Physiologic Contract

4.1 Primary goals (non-negotiable)

1. Protect diastolic pressure / CPP (avoid abrupt SVR drops)
2. Avoid tachycardia (reduce demand; preserve diastolic time)
3. Maintain preload (hypertrophied LV is preload-sensitive)
4. Avoid hypoxia/hypercarbia/acidosis (especially with PA stenosis)
5. Avoid wide BP/HR swings (low buffering capacity) [3–6].

4.2 Common failure modes (high-yield “do not do” list)

• Rapid vasodilation early in induction (large bolus vasodilatory agents; deep volatile before stabilization)
• Intubation stimulation without adequate depth/analgesia → tachycardia + BP swings
• Aggressive positive-pressure ventilation without preload/vasopressor readiness
• Underestimating fasting-related hypovolemia in a preload-sensitive LV [3–6].

5) Induction Strategy: Principles and Safety Architecture

5.1 Before the first drug: build the runway

• Explicit team brief: “SVAS induction = coronary perfusion risk.”
• Reliable access (≥1–2 IVs as feasible); plan for arterial line timing based on cooperation and severity.
• Vasoactive support immediately available (push-dose strategy + infusion readiness).
• Defibrillation/pacing capability ready.
• For highest-risk phenotypes: define escalation to ECPR/ECMO standby in advance [3–7].

5.2 Hemodynamic steering: anticipate the two critical transitions

• Loss of sympathetic tone (anesthetic onset) → treat/avoid hypotension promptly.
• Positive-pressure ventilation → anticipate preload reduction and manage ventilatory strategy accordingly.

Evidence-based institutional approaches have shown that structured peri-anesthesia guidelines and modified induction management can reduce adverse-event frequency compared with historical practice, supporting the value of protocolization in this high-risk physiology [6,7].

6) Evidence Base: What the Literature Consistently Shows

• Sedation/anesthesia-related catastrophic events in SVAS/Williams syndrome are repeatedly attributed to LVH-driven demand increase plus coronary flow compromise, often involving coronary ostial disease [2–4,8,9].
• Retrospective institutional experience demonstrates non-trivial rates of anesthesia-related hemodynamic/cardiac complications in Williams syndrome cohorts, reinforcing the need for pre-procedure risk stratification and tight hemodynamic control [5].
• Reviews emphasize risk stratification frameworks, with highest-risk profiles including severe SVAS, significant LVH/strain, coronary obstruction, and/or concomitant RVOT/PA obstruction [3,4].
• When collapse occurs and requires mechanical support, registry data suggest outcomes remain guarded, underscoring the importance of prevention and immediate escalation readiness [10].

7) High-Yield Summary (for your slide’s bottom line)

• Induction is high risk in SVAS because common anesthetic effects can rapidly decrease SVR/diastolic pressure, while the hypertrophied LV often has elevated LVEDP and limited coronary reserve, precipitating ischemia and sudden collapse [2–4].
• Coexisting branch PA stenosis amplifies instability via RV afterload stress and preload dependence, creating a “doubly-obstructed” physiology [2,5].
• The operational objective is not simply “avoid hypotension,” but specifically:
• protect diastolic pressure/CPP
• avoid tachycardia
• preserve preload
• avoid HR/BP volatility, and
• ensure protocolized preparation with rapid escalation (including ECMO standby when appropriate) [3–7,10].

References

[1] Collins RT 2nd. Cardiovascular disease in Williams syndrome. Circulation. 2013;127(21):2125-2134.

[2] Burch TM, McGowan FX Jr, Kussman BD, Powell AJ, DiNardo JA. Congenital supravalvular aortic stenosis and sudden death associated with anesthesia: what’s the mystery? Anesth Analg. 2008;107(6):1848-1854.

[3] Matisoff AJ, Olivieri L, Schwartz JM, Deutsch N. Risk assessment and anesthetic management of patients with Williams syndrome: a comprehensive review. Paediatr Anaesth. 2015;25(12):1207-1215.

[4] Collins RT 2nd, Kaplan P, Somes GW, Rome JJ. Peri-procedural risk stratification and management of patients with Williams syndrome. Congenit Heart Dis. 2017;12(2):133-142.

[5] Olsen M, Fahy CJ, Costi DA, Kelly AJ, Burgoyne LL. Anaesthesia-related haemodynamic complications in Williams syndrome patients: a review of one institution’s experience. Anaesth Intensive Care. 2014;42(5):619-624.

[6] Schmidt AR, Collins RT 2nd, Adusumelli S, Ramamoorthy C, Weng C, MacMillen KL, Navaratnam M. Impact of Modified Anesthesia Management for Pediatric Patients With Williams Syndrome. J Cardiothorac Vasc Anesth. 2021;35(9):2609-2617.

[7] Andrews LK, Funk EM, McCormick K, McGinty AM, Delphin ED, Baxley RD, Brasher C, Collins RT 2nd. Characterizing Periprocedural Care for Pediatric Patients With Williams Syndrome Undergoing General Anesthesia at a Tertiary Pediatric Hospital. AANA J. 2025;93(4):290-298.

[8] Horowitz PE, Akhtar S, Wulff JA, Al Fadley F, Al Halees Z. Coronary artery disease and anesthesia-related death in children with Williams syndrome. J Cardiothorac Vasc Anesth. 2002;16(6):739-741.

[9] Yildiz O, Altin FH, Kaya M, Ozyilmaz I, Guzeltas A, Erek E. Left coronary artery stenosis causing left ventricular dysfunction in two children with supravalvular aortic stenosis. World J Pediatr Congenit Heart Surg. 2015;6(2):311-316.

[10] Martin A, Rycus PT, Farooqi A, Dentel J, Cashen K. Extracorporeal membrane oxygenation outcomes in children with Williams syndrome: a review of the ELSO registry. Perfusion. 2022;37(4):359-365.